Cytokine and growth factor profiling in patients with the metabolic syndrome

Seyed Reza Mirhafez; Alireza Pasdar; Amir Avan; Habibollah Esmaily; Atefeh Moezzi; Mohsen Mohebati; Zahra Meshkat; Hassan Mehrad-Majd; Saied Eslami; Hamid Reza Rahimi; Hamed Ghazavi; Gordon A. Ferns; Majid Ghayour-Mobarhan

doi:10.1017/S0007114515001038

Cytokine and growth factor profiling in patients with the metabolic syndrome

Seyed Reza Mirhafez, Alireza Pasdar, Amir Avan, Habibollah Esmaily, Atefeh Moezzi, Mohsen Mohebati, Zahra Meshkat, Hassan Mehrad-Majd, Saied Eslami, Hamid Reza Rahimi, Hamed Ghazavi, Gordon A. Ferns, Majid Ghayour-Mobarhan^*

^*Corresponding author for this work

Applied Medicine

Research output: Contribution to journal › Article › peer-review

73 Citations (Scopus)

Abstract

The metabolic syndrome (MetS) is associated with a pro-inflammatory milieu that may partially account for its association with an increased cardiovascular risk. We aimed to (1) evaluate the serum concentrations of twelve cytokines and growth factors (epidermal growth factor (EGF), interferon-γ (IFN-γ), IL-1α/-1β/-2/-4/-6/-8/-10, monocyte chemoattractant protein-1 (MCP-1), TNF-α and vascular endothelial growth factor (VEGF)) in 303 individuals with or without the MetS; and (2) explore their relationship with the presence of the MetS. Patients with the MetS had significantly higher serum concentrations of IFN-γ, EGF, IL-1α/-1β/-2/-4/-6/-8/-10, MCP-1 and TNF-α, whilst serum VEGF concentrations were markedly lower compared with the control group (e.g. 38-55 v. 82-18 pg/ml; P<0-05). Amongst these parameters, IFN-γ and IL-1α emerged as the most significant independent predictors of the MetS. In conclusion, our findings demonstrate that patients with the MetS had an altered blood cytokine and growth factor profile that may partially account for its adverse clinical outcomes. Further prospective studies in larger multi-centre settings are required to unravel the role and association of the emerging biomarkers with the MetS and their implication in therapeutic intervention.

Original language	English
Pages (from-to)	1911-1919
Number of pages	9
Journal	British Journal of Nutrition
Volume	113
Issue number	12
Early online date	20 May 2015
DOIs	https://doi.org/10.1017/S0007114515001038
Publication status	Published - 28 Jun 2015

Bibliographical note

Acknowledgements
We would like to thank all the patients for their help and participating in the study.

This work was supported by the grant from MUMS, Research Council (M. G.-M., S. R. M., A. A. and A. P.). The results obtained in the present study are part of Mr Seyed Reza Mirhafez's PhD thesis (ID no. 910823) in MUMS. MUMS had no role in the design, analysis or writing of this article.

The authors' contributions are as follows: M. G.-M., A. P. and Z. M. contributed to the study design; S. R. M., M. M. and A. R. H.-B. conducted the experimental part; S. R. M., M. G.-M., H. R. R., S. E., H. M.-M., H. E. and A. M. contributed to the data analysis; S. R. M., A. P., A. A., G. A. F., A. P. and M. G.-M. contributed to the preparation of the manuscript.

The authors have no conflict of interest.

Keywords

Cytokines
Diabetes
Growth factors
Inflammation
Metabolic syndrome

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1017/S0007114515001038

Cite this

@article{fca86493fa4b49b799c3e6b5c3fc07d8,

title = "Cytokine and growth factor profiling in patients with the metabolic syndrome",

abstract = "The metabolic syndrome (MetS) is associated with a pro-inflammatory milieu that may partially account for its association with an increased cardiovascular risk. We aimed to (1) evaluate the serum concentrations of twelve cytokines and growth factors (epidermal growth factor (EGF), interferon-γ (IFN-γ), IL-1α/-1β/-2/-4/-6/-8/-10, monocyte chemoattractant protein-1 (MCP-1), TNF-α and vascular endothelial growth factor (VEGF)) in 303 individuals with or without the MetS; and (2) explore their relationship with the presence of the MetS. Patients with the MetS had significantly higher serum concentrations of IFN-γ, EGF, IL-1α/-1β/-2/-4/-6/-8/-10, MCP-1 and TNF-α, whilst serum VEGF concentrations were markedly lower compared with the control group (e.g. 38-55 v. 82-18 pg/ml; P<0-05). Amongst these parameters, IFN-γ and IL-1α emerged as the most significant independent predictors of the MetS. In conclusion, our findings demonstrate that patients with the MetS had an altered blood cytokine and growth factor profile that may partially account for its adverse clinical outcomes. Further prospective studies in larger multi-centre settings are required to unravel the role and association of the emerging biomarkers with the MetS and their implication in therapeutic intervention.",

keywords = "Cytokines, Diabetes, Growth factors, Inflammation, Metabolic syndrome",

author = "Mirhafez, {Seyed Reza} and Alireza Pasdar and Amir Avan and Habibollah Esmaily and Atefeh Moezzi and Mohsen Mohebati and Zahra Meshkat and Hassan Mehrad-Majd and Saied Eslami and Rahimi, {Hamid Reza} and Hamed Ghazavi and Ferns, {Gordon A.} and Majid Ghayour-Mobarhan",

note = "Acknowledgements We would like to thank all the patients for their help and participating in the study. This work was supported by the grant from MUMS, Research Council (M. G.-M., S. R. M., A. A. and A. P.). The results obtained in the present study are part of Mr Seyed Reza Mirhafez's PhD thesis (ID no. 910823) in MUMS. MUMS had no role in the design, analysis or writing of this article. The authors' contributions are as follows: M. G.-M., A. P. and Z. M. contributed to the study design; S. R. M., M. M. and A. R. H.-B. conducted the experimental part; S. R. M., M. G.-M., H. R. R., S. E., H. M.-M., H. E. and A. M. contributed to the data analysis; S. R. M., A. P., A. A., G. A. F., A. P. and M. G.-M. contributed to the preparation of the manuscript. The authors have no conflict of interest. ",

year = "2015",

month = jun,

day = "28",

doi = "10.1017/S0007114515001038",

language = "English",

volume = "113",

pages = "1911--1919",

journal = "British Journal of Nutrition",

issn = "0007-1145",

publisher = "Cambridge University Press",

number = "12",

}

TY - JOUR

T1 - Cytokine and growth factor profiling in patients with the metabolic syndrome

AU - Mirhafez, Seyed Reza

AU - Pasdar, Alireza

AU - Avan, Amir

AU - Esmaily, Habibollah

AU - Moezzi, Atefeh

AU - Mohebati, Mohsen

AU - Meshkat, Zahra

AU - Mehrad-Majd, Hassan

AU - Eslami, Saied

AU - Rahimi, Hamid Reza

AU - Ghazavi, Hamed

AU - Ferns, Gordon A.

AU - Ghayour-Mobarhan, Majid

N1 - Acknowledgements We would like to thank all the patients for their help and participating in the study. This work was supported by the grant from MUMS, Research Council (M. G.-M., S. R. M., A. A. and A. P.). The results obtained in the present study are part of Mr Seyed Reza Mirhafez's PhD thesis (ID no. 910823) in MUMS. MUMS had no role in the design, analysis or writing of this article. The authors' contributions are as follows: M. G.-M., A. P. and Z. M. contributed to the study design; S. R. M., M. M. and A. R. H.-B. conducted the experimental part; S. R. M., M. G.-M., H. R. R., S. E., H. M.-M., H. E. and A. M. contributed to the data analysis; S. R. M., A. P., A. A., G. A. F., A. P. and M. G.-M. contributed to the preparation of the manuscript. The authors have no conflict of interest.

PY - 2015/6/28

Y1 - 2015/6/28

N2 - The metabolic syndrome (MetS) is associated with a pro-inflammatory milieu that may partially account for its association with an increased cardiovascular risk. We aimed to (1) evaluate the serum concentrations of twelve cytokines and growth factors (epidermal growth factor (EGF), interferon-γ (IFN-γ), IL-1α/-1β/-2/-4/-6/-8/-10, monocyte chemoattractant protein-1 (MCP-1), TNF-α and vascular endothelial growth factor (VEGF)) in 303 individuals with or without the MetS; and (2) explore their relationship with the presence of the MetS. Patients with the MetS had significantly higher serum concentrations of IFN-γ, EGF, IL-1α/-1β/-2/-4/-6/-8/-10, MCP-1 and TNF-α, whilst serum VEGF concentrations were markedly lower compared with the control group (e.g. 38-55 v. 82-18 pg/ml; P<0-05). Amongst these parameters, IFN-γ and IL-1α emerged as the most significant independent predictors of the MetS. In conclusion, our findings demonstrate that patients with the MetS had an altered blood cytokine and growth factor profile that may partially account for its adverse clinical outcomes. Further prospective studies in larger multi-centre settings are required to unravel the role and association of the emerging biomarkers with the MetS and their implication in therapeutic intervention.

AB - The metabolic syndrome (MetS) is associated with a pro-inflammatory milieu that may partially account for its association with an increased cardiovascular risk. We aimed to (1) evaluate the serum concentrations of twelve cytokines and growth factors (epidermal growth factor (EGF), interferon-γ (IFN-γ), IL-1α/-1β/-2/-4/-6/-8/-10, monocyte chemoattractant protein-1 (MCP-1), TNF-α and vascular endothelial growth factor (VEGF)) in 303 individuals with or without the MetS; and (2) explore their relationship with the presence of the MetS. Patients with the MetS had significantly higher serum concentrations of IFN-γ, EGF, IL-1α/-1β/-2/-4/-6/-8/-10, MCP-1 and TNF-α, whilst serum VEGF concentrations were markedly lower compared with the control group (e.g. 38-55 v. 82-18 pg/ml; P<0-05). Amongst these parameters, IFN-γ and IL-1α emerged as the most significant independent predictors of the MetS. In conclusion, our findings demonstrate that patients with the MetS had an altered blood cytokine and growth factor profile that may partially account for its adverse clinical outcomes. Further prospective studies in larger multi-centre settings are required to unravel the role and association of the emerging biomarkers with the MetS and their implication in therapeutic intervention.

KW - Cytokines

KW - Diabetes

KW - Growth factors

KW - Inflammation

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84936891331&partnerID=8YFLogxK

U2 - 10.1017/S0007114515001038

DO - 10.1017/S0007114515001038

M3 - Article

C2 - 25990566

AN - SCOPUS:84936891331

SN - 0007-1145

VL - 113

SP - 1911

EP - 1919

JO - British Journal of Nutrition

JF - British Journal of Nutrition

IS - 12

ER -

Cytokine and growth factor profiling in patients with the metabolic syndrome

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this